Dechra Pharmaceuticals plc Given “Buy” Rating at Investec (DPH)
Dechra Pharmaceuticals plc (LON:DPH)‘s stock had its “buy” rating reiterated by Investec in a research note issued on Wednesday, Analyst Ratings Network.com reports. They currently have a GBX 787 ($13.22) target price on the stock. Investec’s price objective would suggest a potential upside of 11.02% from the stock’s previous close.
Shares of Dechra Pharmaceuticals plc (LON:DPH) traded up 2.59% on Wednesday, hitting GBX 708.88. 212,895 shares of the company’s stock traded hands. Dechra Pharmaceuticals plc has a 52 week low of GBX 655.00 and a 52 week high of GBX 755.00. The stock has a 50-day moving average of GBX 676. and a 200-day moving average of GBX 688.1. The company’s market cap is £618.2 million.
DPH has been the subject of a number of other recent research reports. Analysts at N+1 Singer raised their price target on shares of Dechra Pharmaceuticals plc from GBX 740 ($12.43) to GBX 760 ($12.77) in a research note on Tuesday, March 11th. They now have a “buy” rating on the stock. Separately, analysts at Panmure Gordon reiterated a “buy” rating on shares of Dechra Pharmaceuticals plc in a research note on Tuesday, February 25th. They now have a GBX 850 ($14.28) price target on the stock. Finally, analysts at Nplus1 Brewin upgraded shares of Dechra Pharmaceuticals plc to a “buy” rating in a research note on Tuesday, February 25th. They now have a GBX 785 ($13.19) price target on the stock, up previously from GBX 740 ($12.43). Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of GBX 773.14 ($12.99).
Dechra Pharmaceuticals PLC (LON:DPH) is a holding company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.